Success Metrics

Clinical Success Rate
87.9%

Based on 29 completed trials

Completion Rate
88%(29/33)
Active Trials
2(4%)
Results Posted
97%(28 trials)
Terminated
4(9%)

Phase Distribution

Ph phase_2
9
20%
Ph phase_1
8
18%
Ph phase_3
6
13%
Ph not_applicable
1
2%
Ph phase_4
13
29%

Phase Distribution

8

Early Stage

9

Mid Stage

19

Late Stage

Phase Distribution37 total trials
Phase 1Safety & dosage
8(21.6%)
Phase 2Efficacy & side effects
9(24.3%)
Phase 3Large-scale testing
6(16.2%)
Phase 4Post-market surveillance
13(35.1%)
N/ANon-phased studies
1(2.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.9%

29 of 35 finished

Non-Completion Rate

17.1%

6 ended early

Currently Active

2

trials recruiting

Total Trials

45

all time

Status Distribution
Active(3)
Completed(29)
Terminated(6)
Other(7)

Detailed Status

Completed29
unknown7
Terminated4
Recruiting2
Withdrawn2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
45
Active
2
Success Rate
87.9%
Most Advanced
Phase 4

Trials by Phase

Phase 18 (21.6%)
Phase 29 (24.3%)
Phase 36 (16.2%)
Phase 413 (35.1%)
N/A1 (2.7%)

Trials by Status

recruiting24%
enrolling_by_invitation12%
terminated49%
completed2964%
unknown716%
withdrawn24%

Recent Activity

2 active trials
Showing 5 of 45
completedphase_4

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

NCT04252742
recruiting

China HeadAche DIsorders RegiStry

NCT05334927
terminated

Migraine Survey in Gulf Region

NCT06237062
completedphase_2

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH

NCT04098250
completedphase_3

Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

NCT03867201
View all 45 trials

Clinical Trials (45)

Showing 20 of 45 trialsScroll for more
NCT04252742Phase 4

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

Completed
NCT05334927

China HeadAche DIsorders RegiStry

Recruiting
NCT06237062

Migraine Survey in Gulf Region

Terminated
NCT04098250Phase 2

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH

Completed
NCT03867201Phase 3

Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

Completed
NCT06212661

Migraine Medication Effects on Urinary Symptoms

Enrolling By Invitation
NCT06411067Phase 3

Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain

Withdrawn
NCT04628429

CGRP Inhibition, Autonomic Function, and Migraine

Recruiting
NCT04084314Phase 4

Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

Completed
NCT04825678Phase 4

A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

Completed
NCT04265755Phase 4

Biomarker and Genetic Predictors of Erenumab Treatment Response

Completed
NCT05284019Phase 4

Real World Effectiveness of Eptinezumab in Participants With Migraine

Terminated
NCT03812224Phase 3

A Controlled Trial of Erenumab in Migraine Prevention

Completed
NCT04970355Phase 2

Efficacy of Erenumab in Chronic Cluster Headache

Completed
NCT03773562Phase 4

Imaging the Migraine Brain Pre- and Post-Erenumab

Completed
NCT04303845Phase 2

Erenumab For Treatment of Hemicrania Continua

Terminated
NCT04592952Phase 4

Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

Unknown
NCT05281770

Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

Unknown
NCT02483585Phase 3

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

Completed
NCT02456740Phase 3

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Completed

Drug Details

Intervention Type
DRUG
Total Trials
45